These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29525577)

  • 21. Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China.
    Li X; Jan S; Yan LL; Hayes A; Chu Y; Wang H; Feng X; Niu W; He FJ; Ma J; Han Y; MacGregor GA; Wu Y
    PLoS One; 2017; 12(9):e0183033. PubMed ID: 28902880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM; Goh J; Johnston A; Falvey H; Brede Y; Brown RE
    J Med Econ; 2012; 15(2):253-60. PubMed ID: 22084957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
    Zhou YF; Liu N; Wang P; Jeong Yang J; Song XY; Pan XF; Zhang X; He M; Li H; Gao YT; Xiang YB; Wu T; Yu D; Pan A
    Hypertension; 2020 Sep; 76(3):750-758. PubMed ID: 32713271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study.
    Das H; Moran AE; Pathni AK; Sharma B; Kunwar A; Deo S
    Glob Heart; 2021 May; 16(1):37. PubMed ID: 34040950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
    Vasudeva E; Moise N; Huang C; Mason A; Penko J; Goldman L; Coxson PG; Bibbins-Domingo K; Moran AE
    Am J Hypertens; 2016 Oct; 29(10):1195-205. PubMed ID: 27172970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of renin-guided treatment of hypertension.
    Smith SM; Campbell JD
    Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China.
    Wang Z; Hao G; Wang X; Chen Z; Zhang L; Zhang Z; Hu H; Weintraub WS; Gao R;
    J Clin Hypertens (Greenwich); 2019 Aug; 21(8):1212-1220. PubMed ID: 31267666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X; Vondeling H
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of new blood pressure target for hypertensive patients in Taiwan according to the 2022 hypertension clinical practice guidelines of the Taiwan society of cardiology: a simulation modeling study.
    Liao CT; Toh HS; Yang CT; Hsu CY; Lee MC; Chang WT; Chen ZC; Chang HY; Strong C
    Hypertens Res; 2023 Jan; 46(1):187-199. PubMed ID: 36229527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
    Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
    J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city.
    Tang JL; Wang WZ; An JG; Hu YH; Cheng SH; Griffiths S
    Int J Epidemiol; 2010 Feb; 39(1):244-54. PubMed ID: 19491141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.